474 related articles for article (PubMed ID: 37608730)
21. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
22. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
23. A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France.
Bresse X; Adam M; Largeron N; Roze S; Marty R
Hum Vaccin Immunother; 2013 Apr; 9(4):823-33. PubMed ID: 23563511
[TBL] [Abstract][Full Text] [Related]
24. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys.
Burger EA; Sy S; Nygård M; Kristiansen IS; Kim JJ
PLoS One; 2014; 9(3):e89974. PubMed ID: 24651645
[TBL] [Abstract][Full Text] [Related]
25. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
26. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States.
Durham DP; Ndeffo-Mbah ML; Skrip LA; Jones FK; Bauch CT; Galvani AP
Proc Natl Acad Sci U S A; 2016 May; 113(18):5107-12. PubMed ID: 27091978
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.
Annemans L; Rémy V; Oyee J; Largeron N
Pharmacoeconomics; 2009; 27(3):231-45. PubMed ID: 19354343
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
29. Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis.
Portnoy A; Pedersen K; Trogstad L; Hansen BT; Feiring B; Laake I; Smith MA; Sy S; Nygård M; Kim JJ; Burger EA
Prev Med; 2021 Mar; 144():106276. PubMed ID: 33678239
[TBL] [Abstract][Full Text] [Related]
30. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States.
Brisson M; Laprise JF; Chesson HW; Drolet M; Malagón T; Boily MC; Markowitz LE
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26438574
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus vaccination at the national and provincial levels in China: a cost-effectiveness analysis using the PRIME model.
Zhou L; Gu B; Wang J; Liu G; Zhang X
BMC Public Health; 2022 Apr; 22(1):777. PubMed ID: 35436877
[TBL] [Abstract][Full Text] [Related]
32. Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study.
Abbas KM; van Zandvoort K; Brisson M; Jit M
Lancet Glob Health; 2020 Apr; 8(4):e536-e544. PubMed ID: 32105613
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
34. Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.
Choi HCW; Jit M; Leung GM; Tsui KL; Wu JT
BMC Med; 2018 Aug; 16(1):127. PubMed ID: 30115065
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of human papillomavirus (HPV) vaccination in Burkina Faso: a modelling study.
Kiendrébéogo JA; Sidibe ARO; Compaoré GB; Nacanabo R; Sory O; Ouédraogo I; Nawaz S; Schuind AE; Clark A
BMC Health Serv Res; 2023 Dec; 23(1):1338. PubMed ID: 38041075
[TBL] [Abstract][Full Text] [Related]
36. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
37. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
38. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
Wahab MT; Tan RKJ; Cook AR; Prem K
Vaccine; 2023 Mar; 41(12):1934-1942. PubMed ID: 36797100
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
Linertová R; Guirado-Fuentes C; Mar-Medina J; Teljeur C
Hum Vaccin Immunother; 2022 Nov; 18(6):2127983. PubMed ID: 36347243
[TBL] [Abstract][Full Text] [Related]
40. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
